Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) and XBiotech (NASDAQ:XBIT – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.
Institutional & Insider Ownership
90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Comparatively, 30.8% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings and price targets for Tarsus Pharmaceuticals and XBiotech, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tarsus Pharmaceuticals | 1 | 2 | 4 | 2 | 2.78 |
| XBiotech | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Tarsus Pharmaceuticals and XBiotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tarsus Pharmaceuticals | -9.02% | -14.19% | -8.89% |
| XBiotech | N/A | -26.10% | -25.06% |
Risk and Volatility
Tarsus Pharmaceuticals has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, XBiotech has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.
Earnings and Valuation
This table compares Tarsus Pharmaceuticals and XBiotech”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tarsus Pharmaceuticals | $451.36 million | 6.00 | -$66.42 million | ($1.14) | -55.19 |
| XBiotech | N/A | N/A | -$45.54 million | ($1.32) | -1.77 |
XBiotech has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.
Summary
Tarsus Pharmaceuticals beats XBiotech on 9 of the 14 factors compared between the two stocks.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
About XBiotech
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
